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For many years European governments have sought to
ensure a high degree of competition in off-patent pharma-
ceutical markets in order to generate price competition -
and consequently benefits such as improved patient access
or savings for payers after patent expiry. The pharmaceuti-
cal industry believes that access to valuable new treat-
ments and post-exclusivity competition are essential for
the sustainability of healthcare systems.
Biological medicines have become increasingly impor-
tant over the last years. Twenty-seven per cent of phar-
maceutical sales in Europe come from biological
medicines. This market grew by 5.5% vs. a total market
growth of 1.9% in value sales between 2012 and 2013.
Many of Europe’s top selling biologic molecules are
facing patent expiry by 2020 [1].
Most biological medicines come at a high cost and
governments have difficulty in coping with these costs
in their constrained pharmaceutical budgets, especially
in current times of austerity. To date, biosimilars
account for less than 0.5% of the $221 billion market of
biological medicines worldwide. Biosimilars can bring
huge savings for payers, and will increase the access to
medicines for patients who could not otherwise afford
treatment [2].
Governments must realize that biosimilar medicines
are different to generic medicines and as such a unique
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Figure 1 The biologics Market - IMS Health Thought Leadership, September 2013
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approach is needed. By applying the generic pricing
model to biosimilar medicines, governments risk mark-
ing the biosimilar market unsustainable and patients
and payers will no longer benefit.
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